Open access
FOLFIRINOX vs. gemcitabine/nab-paclitaxel for metastatic pancreatic cancer: A real-world study
Jeehoon Kim
See-Young Lee
Galam Leem
H. Lee
S. Jang
Moon-Jae Chung
J. Park
Seungmin Bang
S. Park
Si-Young Song
Jae-Hee Cho
J. Jo
Medicine
Abstract
Highlights • No significant OS or PFS differences were observed between regimens after matching.• Survival differences before matching may partly reflect patient selection.• ARID1A and RNF43 mutations were associated with shorter PFS with Gem/Nab-P.• Exploratory genomic associations require validation in larger prospective cohorts.